Axinn partners Matt Becker and Aziz Burgy will speak at American Conference Institute's 9th Annual Paragraph IV Disputes Master Symposium, being held October 24-25 in Chicago. 

On October 24, Aziz will speak on a panel entitled, "Insights and Impacts of Amgen v. Sanofi: Satisfying the Requirements of Enablement Provisions & Written Description and the Future of §112." Panelists will discuss: 

• The Supreme Court’s consideration of the enablement requirement taking stock of what the decision means when a patent claims a class of novel compounds or antibodies.
• The impact of the decision on the ability to protect broader foundational innovations and the impact of other influential §112 cases like Juno, Biogen and Idenix.
• Whether patentees must disclose enough information to “enable” people of ordinary skill in the relevant art to “reach the full scope” of a claimed invention.
•  Implementing best practices for patent prosecution in view of the decision and strengthening and invalidating patent claims moving post Amgen v. Sanofi.

On October 25, Matt will speak on a panel entitled, "Revisiting Damages in an At-Risk Launch Scenario: Questions of Remedies, Valuation, and New Scenarios Post GSK v. Teva." Panelists will discuss: 

• Questions of royalties, lost profits, and exceptional findings. 
• Grounds for mitigation.
• Practical consequences of the Supreme Court’s WesternGeco decision on Hatch-Waxman damages awards and when US patent owners may recover foreign lost profits tied to domestic acts of infringement under § 271(f)(2).

• Cases where the relevant infringing conduct occurred in the United States. 

Click here to learn more, including how to register.